Diagnostic proteomics: Serum proteomic patterns for the detection of early stage cancers

Disease Markers

Volumn 19, Issue 4-5, 2003, Pages 209-218

  Yu, Li Rong ^a   Zhou, Ming ^a   Conrads, Thomas P ^a   Veenstra, Timothy D ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Cancer detection; Mass spectrometry; Proteomic patterns; Serum

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER STAGING; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 3042751840     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/612071     Document Type: Article

References (26)

1. B.L. Adam, Y. Qu, J.W. Davis, M.D. Ward, M.A. Clements, L.H. Cazares, O.J. Semmes, P.F. Schellhammer, Y. Yasui, Z. Feng and G.L. Wright Jr., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res 62 (2002), 3609-3614.
2. J.N. Adkins, S.M. Varnum, K.J. Auberry, R.J. Moore, N.H. Angell, R.D. Smith, D.L. Springer and J.G. Pounds, Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry, Mol Cell Proteomics 1 (2002), 947-955.
3. R.C. Bast, Status of tumor markers in ovarian cancer screening, J Clin Oncol 21 (2003), 200s-205s.
4. L.H. Cazares, B.L. Adam, M.D. Ward, S. Nasim, P.F. Schellhammer, O.J. Semmes and G.L. Wright Jr., Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry, Clin Cancer Res 8 (2002), 2541-2552.
5. H. Christensen, H.H. Thyssen, O. Schebye and A. Berget, Three highly sensitive bedside serum and urine tests for pregnancy compared, Clin Chem 36 (1990), 1686-1688.
6. T.P. Conrads, M. Zhou, E.F. Petricoin, L. Liotta and T.D. Veenstra, Cancer diagnosis using proteomic patterns, Exp Rev Mol Diag 3 (2003), 411-420.
7. E.P. Diamandis, Proteomic patterns in serum and identification of ovarian cancer, Lancet 360 (2002), 170.
8. D.J. Grossklaus, J.A. Smith, S.B. Shappell, C.S. Coffey, S.S. Chang and M.S. Cookson, The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA, Urol Oncol 7 (2002), 195-198.
9. A.E. Guppy and G.J. Rustin, CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 (2002), 437-443.
10. S. Hanash, Disease proteomics, Nature 422 (2003), 226-232.
11. J.H. Holland, in: Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence, J.H. Holland, ed., MIT Press, Cambridge, MA USA.
12. H.J. Issaq, T.P. Conrads, D.A. Prieto, R. Tirumalai and T.D. Veenstra, SELDI-TOF MS for diagnostic proteomics, Anal Chem 75 (2003), 149A-155A.
13. K.K. Jain, Role of proteomics in diagnosis of cancer, Technol Cancer Res Treat 1 (2002), 281-286.
14. C. Kainz, Early detection and preoperative diagnosis of ovarian carcinoma, Wien. Med. Wochenschr 146 (1996), 2-7.
15. Y. Kohonen, Biological Cybernetics 43 (1982), 59-69.
16. Y. Kohonen, Proc. Inst. Electrical Electronics Eng. 78 (1990), 1464-1480.
17. J. Li, Z. Zhang, J. Rosenzweig, Y.Y. Wang and D.W. Chan, Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin Chem 48 (2002), 1296-1304.
18. R.F. Ozols, S.C. Rubin, G.M. Thomas, and S.J. Robboy, in: Epithelial Ovarian Cancer, W.J. Hoskins, C.A. Perez and R.C. Young, eds, Principles and Practice of Gynecologic OncologyLippincott Williams and Wilkins, Philadelphia, PA USA, pp. 981-1058.
19. E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, G.B. Mills, C. Simone, D.A. Fishman, E.C. Kohn and L.A. Liotta, Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 (2002), 572-577.
20. E.F. Petricoin, D.K. Ornstein, C.P. Paweletz, A. Ardekani, P.S. Hackett, B.A. Hitt, A. Velassco, C. Trucco, L. Wiegand, K. Wood, C.B. Simone, P.J. Levine, W.M. Linehan, M.R. Emmert-Buck, S.M. Steinberg, E.C. Kohn and L.A. Liotta, Serum proteomic patterns for detection of prostate cancer, J. Natl. Cancer Inst 94 (2002), 1576-1578.
21. Y. Qu, B.L. Adam, Y. Yasui, M.D. Ward, L.H. Cazares, P.F. Schellhammer, Z. Feng, O.J. Semmes and C.L. Wright Jr., Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients, Clin Chem 48 (2002), 1835-1843.
22. R. Tirumalai, K.C. Chan, D.A. Prieto, H.J. Issaq, T.P. Conrads and T.D. Veenstra, Characterization of the low molecular weight human serum proteome, Mol. Cell. Proteomics 2 (2003), 1096-1103.
23. S.L. Wu, H. Amato, R. Biringer, G. Choudhary, P. Shieh and W.S. Hancock, Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system, J. Proteome Res 1 (2002), 459-465.
24. K. Yanagisawa, Y. Shyr, B.J. Xu, P.P. Massion, P.H. Larsen, B.C. White, J.R. Roberts, M. Edgerton, A. Gonzalez, S. Nadaf, J.H. Moore, R.M. Caprioli and D.P. Carbone, Proteomic patterns of tumour subsets in non-small-cell lung cancer, Lancet 362 (2003), 433-439.
25. L.R. Yu, M.D. Johnson, T.P. Conrads, R.D. Smith, R.S. Morrison and T.D. Veenstra, Proteome analysis of camptothecin-treated cortical neurons using isotope-coded affinity tags, Electrophoresis 23 (2002), 1591-1598.
26. Z. Xiao, T.P. Conrads, D.A. Lucas, G.M. Janini, C.F. Schaefer, K.H. Buetow, H.J. Issaq and T.D. Veenstra, Direct ampholyte-free liquid phase isoelectric peptide focusing: Application to the human serum proteome, Electrophoresis, In press.